AAIC 2026 Emerging Therapeutic Targets

AAIC 2026 showcases significant advances in Alzheimer's disease and dementia therapeutics, with emerging targets in four key areas: neuroinflammation modulation, synaptic function preservation, metabolic approaches, and gene therapy. These novel mechanisms represent the next frontier in disease-modifying therapies beyond anti-amyloid approaches.

Overview

The therapeutic pipeline at AAIC 2026 demonstrates a maturation of the field beyond amyloid-targeting strategies. While anti-amyloid antibodies like [lecanemab](/therapeutics/lecanemab) and [donanemab](/therapeutics/donanemab) continue to generate real-world data, the conference highlights a broader portfolio of targets addressing multiple pathological hallmarks of neurodegenerative diseases[@antiamyloid].

Neuroinflammation Modulation

Microglial Dysfunction as a Therapeutic Target

Microglial cells, the resident immune cells of the brain, have emerged as critical players in Alzheimer's disease pathogenesis. At AAIC 2026, several programs target microglial signaling pathways:

TREM2 Signaling Pathway:
The triggering receptor expressed on myeloid cells 2 (TREM2) represents one of the most promising microglial targets. TREM2 variants significantly increase Alzheimer's disease risk, and therapeutic agonism of TREM2 may restore beneficial microglial functions[@trem].

• TREM2 agonists in development aim to enhance microglial phagocytosis of amyloid plaques
• TREM2-independent pathways targetingTYROBP (DAP12) adaptor protein
• CD33 modulation to reduce inhibitory microglial signaling

AAIC 2026 showcases significant advances in Alzheimer's disease and dementia therapeutics, with emerging targets in four key areas: neuroinflammation modulation, synaptic function preservation, metabolic approaches, and gene therapy. These novel mechanisms represent the next frontier in disease-modifying therapies beyond anti-amyloid approaches.

Overview

The therapeutic pipeline at AAIC 2026 demonstrates a maturation of the field beyond amyloid-targeting strategies. While anti-amyloid antibodies like [lecanemab](/therapeutics/lecanemab) and [donanemab](/therapeutics/donanemab) continue to generate real-world data, the conference highlights a broader portfolio of targets addressing multiple pathological hallmarks of neurodegenerative diseases[@antiamyloid].

Neuroinflammation Modulation

Microglial Dysfunction as a Therapeutic Target

Microglial cells, the resident immune cells of the brain, have emerged as critical players in Alzheimer's disease pathogenesis. At AAIC 2026, several programs target microglial signaling pathways:

TREM2 Signaling Pathway:
The triggering receptor expressed on myeloid cells 2 (TREM2) represents one of the most promising microglial targets. TREM2 variants significantly increase Alzheimer's disease risk, and therapeutic agonism of TREM2 may restore beneficial microglial functions[@trem].

• TREM2 agonists in development aim to enhance microglial phagocytosis of amyloid plaques
• TREM2-independent pathways targetingTYROBP (DAP12) adaptor protein
• CD33 modulation to reduce inhibitory microglial signaling

| Program | Mechanism | Company | Stage |
|---------|-----------|---------|-------|
| AL002 | TREM2 agonist | Alector/GSK | Phase II |
| SAR-443122 | TREM2 inverse agonist | Sanofi | Phase I |

Neuroinflammation Mechanisms

The neuroinflammatory cascade in Alzheimer's involves multiple signaling pathways:

Cytokine-targeted approaches:

• IL-1beta neutralizing antibodies
• TNF-alpha inhibition
• IL-6 receptor blockade

Synaptic Function Preservation

Synaptic loss correlates most strongly with cognitive decline in Alzheimer's disease, making synaptic protection a critical therapeutic goal. AAIC 2026 highlights several approaches:

Synaptic Plasticity Mechanisms

Key targets for synaptic preservation:

| Target | Function | Therapeutic Approach |
|--------|----------|---------------------|
| PSD-95 | postsynaptic scaffold | Stabilization compounds |
| Synapsin | vesicle regulation | Phosphorylation modulators |
| NMDA receptor | calcium influx | Partial agonists |
| AMPA receptor | fast excitatory transmission | Positive allosteric modulators |

Synaptic Dysfunction Mechanisms

The [synaptic dysfunction](/mechanisms/synaptic-dysfunction) pathway involves multiple molecular steps that can be targeted therapeutically:

Amyloid-beta oligomer effects on synapses:

• Direct binding to NMDA and AMPA receptors
• Disruption of receptor trafficking
• Induction of excitotoxicity
• Impairment of long-term potentiation (LTP)

• Mislocalization of tau to synapses
• Disruption of synaptic vesicle trafficking
• Prion-like propagation along neuronal circuits

• Synaptic protective agents
• Receptor density stabilizers
• Calcium homeostasis modulators
• Dendritic spine preservation compounds

Metabolic Approaches

Brain Energy Metabolism in Alzheimer's

Cerebral hypometabolism is an early feature of Alzheimer's disease, and metabolic approaches aim to restore brain energy homeostasis. AAIC 2026 features programs targeting:

NAD+ Metabolism:
Nicotinamide adenine dinucleotide (NAD+) depletion occurs in aging and Alzheimer's brain. NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are being investigated[@nad].

Mitochondrial Function:

• Mitophagy enhancers
• Mitochondrial biogenesis stimulators
• ATP production supporters

• Lactate shuttle enhancers
• Astrocytic glucose transporter modulators

Metabolic Therapy Approaches

| Approach | Mechanism | Stage |
|----------|-----------|-------|
| NAD+ precursors | Restore cellular energy | Phase II |
| Mitolytics | Clear damaged mitochondria | Preclinical |
| Glycolysis enhancers | Improve glucose utilization | Phase I |

Gene Therapy Developments

Gene therapy for neurodegenerative diseases has matured significantly, with multiple programs advancing to clinical stages. AAIC 2026 highlights include:

AAV Vector Delivery

[AAV gene therapy](/therapeutics/aav-gene-therapy-neurodegeneration) for CNS disorders has made major advances:

Key developments:

• Enhanced CNS-penetrant AAV capsids
• Improved delivery to specific cell types
• Manufacturing scale-up for clinical supply

Gene Therapy Targets

| Target | Disease | Vector | Company |
|--------|---------|--------|---------|
| GBA1 | PD/Gaucher | AAV | Prev Ambrosia/Spark |
| LRRK2 | Parkinson's | AAV | Multiple |
| APOE4 | Alzheimer's | AAV | Voyager |

Gene Editing Approaches

[CRISPR gene editing](/therapeutics/crispr-cas9-gene-therapy-neurodegeneration) technologies are advancing toward clinical application:

• Base editing for precise nucleotide changes
• In vivo gene editing delivery systems
• Epigenetic modulators for gene expression

Antisense Oligonucleotides

ASO technology has shown success in neurological diseases:

• Targets for tau protein reduction
• Alpha-synuclein lowering
• TREM2 modulation

Therapeutic Pipeline Summary

Clinical Trial Landscape

AAIC 2026 features updates from multiple late-stage clinical trials:

Phase III Programs:

• Anti-amyloid antibodies: Long-term outcome data
• Anti-tau immunotherapies: Multiple epitopes in development

• TREM2 agonists: Dose-finding and efficacy signals
• Synaptic function modulators: Cognitive endpoint results
• Metabolic agents: Biomarker-driven selection

• Novel mechanisms entering clinical testing
• Combination therapy approaches
• Gene therapy and gene editing

Future Directions

The therapeutic landscape at AAIC 2026 demonstrates a maturing field moving toward multi-target approaches:

Related NeuroWiki Content

• [AAIC 2026 Conference](/events/aaic-2026)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [TREM2 Signaling Pathway](/mechanisms/trem2-signaling)
• [Synaptic Dysfunction Mechanisms](/mechanisms/synaptic-dysfunction)
• [Metabolic Dysfunction in Alzheimer's](/mechanisms/metabolic-dysfunction-alzheimers)
• [Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy-neurodegeneration)
• [AAV Gene Therapy](/therapeutics/aav-gene-therapy-neurodegeneration)

References